Starling Oncology, Inc.
STLN· Nasdaq
STLNStarling Oncology, Inc.
Filed Nov 9, 2022 · 10-Q · 40 days after period end · 0001628280-22-029268
| Metric | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|
| Revenue | $64.98M | $52.28M | — |
| Net Income | -$2.67M | -$432.03K | -$137.66K |
| EPS Diluted | -$0.17 | -$0.05 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Starling Oncology, Inc. · CIK 1799191 · Engraved from SEC EDGAR
ended Sep 30, 2022 · filed Nov 9, 2022 · 40 d after period end
